Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196640 | 0.90 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13486250 | 0.81 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL3129095 | 0.81 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL1157624 | 0.80 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL4194607 | 0.80 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL3120647 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL1157571 | 0.79 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4202645 | 0.79 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3126389 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL4198463 | 0.79 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.